Paul Chamberlin has significant experience in cardiovascular research and development. He joined Imbria as head of clinical development from Ironwood and was in June 2021 promoted to Senior Vice President, Clinical development. Prior to Ironwood, he held leadership positions at multiple start-up biotechnology companies. He was part of the launch team at Ventrix, serving as Chief Medical Officer; was VP of Medical Development at Sequel Pharmaceuticals; and led research and clinical development of cardiac drugs for the treatment of heart failure and atrial fibrillation at NovaCardia. Before NovaCardia, Dr. Chamberlin served in various positions of increasing responsibility at EPIX Pharmaceuticals, including as Executive Medical Director. He started his career in healthcare strategy consulting at Arthur D. Little and the biotechnology division of Rhone-Poulenc-Rorer (now Sanofi). Dr. Chamberlin holds an MD from Boston University and a BA in Biology from the University of Pennsylvania.